A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720

• James S. McCarthy ,

  * E-mail: J.McCarthy@uq.edu.au

  Affiliation Queensland Institute of Medical Research (QIMR), University of Queensland, Brisbane, Australia

  ⨯
• Joanne Marjason,

  Affiliation Q-Pharm Pty Ltd, Brisbane, Australia

  ⨯
• Suzanne Elliott,

  Affiliation Q-Pharm Pty Ltd, Brisbane, Australia

  ⨯
• Paul Fahey,

  Affiliation PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America

  ⨯
• Gilles Bang,

  Affiliation Institut Pasteur, Paris, France

  ⨯
• Elissa Malkin,

  Affiliation PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America

  ⨯
• Eveline Tierney,

  Affiliation PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America

  ⨯
• Hayley Aked-Hurditch,

  Affiliation Q-Pharm Pty Ltd, Brisbane, Australia

  ⨯
• Christopher Adda,

  Affiliation Department of Biochemistry, La Trobe University, Melbourne, Australia

  ⨯
• Nadia Cross,

  Affiliation Walter and Eliza Hall Institute, Parkville, Victoria, Australia

  ⨯
• Jack S. Richards,

  Affiliation Walter and Eliza Hall Institute, Parkville, Victoria, Australia

  ⨯
• Freya J. I. Fowkes,

  Affiliation Walter and Eliza Hall Institute, Parkville, Victoria, Australia

  ⨯
• Michelle J. Boyle,

  Affiliation Walter and Eliza Hall Institute, Parkville, Victoria, Australia

  ⨯
• Carole Long,

  Affiliation National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Pierre Druilhe,

  Affiliation Institut Pasteur, Paris, France

  ⨯
• James G. Beeson,

  Affiliation Walter and Eliza Hall Institute, Parkville, Victoria, Australia

  ⨯
•  [ ... ],
• Robin F. Anders

  Affiliation Department of Biochemistry, La Trobe University, Melbourne, Australia

  ⨯
• [ view all ]
• [ view less ]